Clinical trials: Neoplasms, Germ Cell and Embryonal
Locally Advanced Metastatic BRAF Mutant Melanoma
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
- Trial name
- NCT01777776
- Testing
- LEE011, LGX818
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 28 people
- Sponsor
- Array BioPharma
Malignant Skin Neoplasm, Melanoma
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote…
- Trial name
- NCT06675643
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Schwannoma
MRI Scan and Intra-labyrinthine Schwannoma
Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state…
- Trial name
- NCT03580850
- Testing
- No intervention in this restrospective study
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Merkel Cell Carcinoma
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Background: Ipilimumab is a drug used to treat melanoma that cannot be treated surgically. It targets a molecule found on T-cells in the human immune system.
- Trial name
- NCT01913691
- Testing
- Ipilimumab
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Glioma
FCI in Post-operative Low Grade Gliomas
The aim of this pilot study is to explore the utility of a new imaging technique, called Field Cycling Imaging (FCI), in postoperative low grade gliomas.
- Trial name
- NCT06294418
- Testing
- Field Cycling Imaging (FCI)
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- NHS Grampian
Head and Neck Squamous Cell Carcinoma, Melanoma
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
- Trial name
- NCT04762225
- Testing
- RPTR-168
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Repertoire Immune Medicines
Malignant Gliomas, Glioblastoma Multiforme
The Safety and Efficacy of DCA for the Treatment of Brain Cancer
Malignant gliomas, which include Glioblastoma multiforme (GBM), are the most common and most aggressive types of brain cancer, accounting for approximately 60% of primary brain tumors.
- Trial name
- NCT00540176
- Testing
- Dichloroacetate (DCA)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk).
- Trial name
- NCT01878617
- Testing
- Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 660 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent High Grade Glioma
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
This trial is an open-label, single-arm, phase 0/1 study of high-grade glioma that aims to evaluate the feasibility, preliminary efficacy and safety of the precision treatment strategy.
- Trial name
- NCT05473923
- Testing
- Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Neuroblastoma
Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma
RATIONALE: Sometimes neuroblastoma will regress without treatment, but sometimes additional treatment may be necessary. Giving more than one chemotherapy drug after surgery to remove the tumor may kill more tumor cells.
- Trial name
- NCT00002803
- Testing
- cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
The HIT-HGG-2013 trial offers an innovative high-quality diagnostics and science program for children and adolescents >3 years, suffering from one of the following types of high grade gliomas: 1.
- Conditions
- Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma
- Trial name
- HIT-HGG-2013 (NCT03243461)
- Testing
- Temozolomide + Valproic Acid
- Where
- 51 sites in Germany
- Volunteers
- 167 people
- Sponsor
- University of Göttingen
Glioma
Craniospinal Irradiation in Histone AlteRed Midline Glioma
Paediatric H3K27/H3G34 mutant diffuse midline gliomas are high grade gliomas that arise in midline structures/cerebral hemispheres and are known to have dismal outcomes.
- Trial name
- CHARM (NCT06720727)
- Testing
- craniospinal irradiation
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Tata Memorial Centre
Glioblastoma, Brain Cancer
Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients
Glioblastoma is the most common and the most aggressive primary brain cancer in adults. Indeed, despite very intensive treatments (i.e.
- Trial name
- ONCOVIRAC (NCT03294486)
- Testing
- Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioblastoma
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma.
- Trial name
- MOSAIC (NCT06183983)
- Testing
- Extended or additional MRI-scan (with contrast) prior to radiotherapy
- Where
- Netherlands
- Volunteers
- 53 people
- Sponsor
- Erasmus Medical Center
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma, Anaplastic Astrocytoma
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).
- Trial name
- NCT03603405
- Testing
- ADV/HSV-tk (gene therapy)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- The Methodist Hospital Research Institute
Anaplastic Astrocytoma, Anaplastic Ependymoma
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
This pilot phase I clinical trial studies how well lapatinib ditosylate before surgery works in treating patients with high-grade glioma that has come back after a period of time during which the tumor could not be detected.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma
- Trial name
- NCT02101905
- Testing
- Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Depression
The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients
Primary tumor glioblastoma is the most common malignant brain. Standard treatment includes biopsy or excision of the tumor in order to obtain a pathological diagnosis, and tumor mass reduction.
- Trial name
- NCT02443194
- Testing
- duloxetine
- Volunteers
- 50 people
- Sponsor
- michal roll
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.